PMID- 31256594
OWN - NLM
STAT- MEDLINE
DCOM- 20200814
LR  - 20200814
IS  - 1735-3947 (Electronic)
IS  - 1029-2977 (Linking)
VI  - 22
IP  - 5
DP  - 2019 May 1
TI  - Intravenous Immunoglobin Utilization Study in a Teaching Hospital.
PG  - 232-235
AB  - BACKGROUND: Intravenous immunoglobulin (IVIG) is an immunomodulating agent that 
      has several actions. The aim of this study was to investigate the indications of 
      IVIG according to available evidence and the cost in our center. METHODS: This 
      retrospective study was conducted between September 2017 and June 2018 at a 
      teaching hospital affiliated with Iran University of Medical Sciences, Tehran, 
      Iran. Patients' demographic data and disease, indication for IVIG use, its dosage 
      and treatment regimen and previous and concurrent treatments were assessed. The 
      collected data were compared with the present criteria for the pattern of IVIG 
      usage. The last version of Lexicomp(R) was used as the reference for indications of 
      the administrated drug and its dosage. RESULTS: A total of 119 patients received 
      IVIG during the study period. The wards with the most frequent IVIG prescription 
      were the neurology (46.2%) and neonatal intensive care unit (21%). The most 
      common reasons of IVIG therapy were various inflammatory neurological disorders. 
      IVIG was used in 22, 43 and 54 cases according to on-label, off- label and other 
      indications, respectively. The total price was higher for off-label indications 
      for IVIG ($254343.75) than on-label indications ($152625). As well, $107250 was 
      exhausted for cases in which there was not sufficient evidence. CONCLUSION: One 
      important aspects of this study was the use of IVIG in cases other than on-label 
      indications. Although a number of studies support IVIG therapy in some diseases, 
      further trials are needed to establish efficacy and safety in these fields.
CI  - (c) 2019 The Author(s). This is an open-access article distributed under the terms 
      of the Creative Commons Attribution License 
      (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, 
      distribution, and reproduction in any medium, provided the original work is 
      properly cited.
FAU - Rezaie, Nader
AU  - Rezaie N
AD  - Department of Pulmonology, Firoozgar Clinical Research Development Center 
      (FCRDC), Iran University of Medical Sciences, Tehran, Iran.
FAU - Shajareh, Elham
AU  - Shajareh E
AD  - Firoozgar Clinical Research Development Center (FCRDC), Iran University of 
      Medical Sciences, Tehran, Iran.
FAU - Motamed, Mohammad Reza
AU  - Motamed MR
AD  - Department of Neurology, Firoozgar Clinical Research Development Center (FCRDC), 
      Iran University of Medical Sciences, Tehran, Iran.
FAU - Ghanbari, Behrooz
AU  - Ghanbari B
AD  - Gastrointestinal and Liver Disease Research Center, Iran University of Medical 
      Sciences, Tehran, Iran.
FAU - Pakdaman, Nashmin
AU  - Pakdaman N
AD  - Firoozgar Clinical Research Development Center (FCRDC), Iran University of 
      Medical Sciences, Tehran, Iran.
FAU - Farasatinasab, Maryam
AU  - Farasatinasab M
AD  - Department of Clinical Pharmacy, Firoozgar Clinical Research Development Center 
      (FCRDC), School of Pharmacy-International Campus, Iran University of Medical 
      Sciences, Tehran, Iran.
LA  - eng
PT  - Journal Article
DEP - 20190501
PL  - Iran
TA  - Arch Iran Med
JT  - Archives of Iranian medicine
JID - 100889644
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Child
MH  - Child, Preschool
MH  - Cross-Sectional Studies
MH  - Drug Costs
MH  - Drug Utilization
MH  - Female
MH  - Hospitals, Teaching
MH  - Humans
MH  - Immunoglobulins, Intravenous/economics/*therapeutic use
MH  - Infant
MH  - Infant, Newborn
MH  - Intensive Care Units, Neonatal/*statistics & numerical data
MH  - Iran
MH  - Male
MH  - Middle Aged
MH  - Neurology/*statistics & numerical data
MH  - Practice Patterns, Physicians'/statistics & numerical data
MH  - Retrospective Studies
MH  - Young Adult
OTO - NOTNLM
OT  - Drug utilization evaluation
OT  - IVIG
OT  - Inflammatory neurological disorders
OT  - Intravenous immunoglobulin
EDAT- 2019/07/02 06:00
MHDA- 2020/08/15 06:00
CRDT- 2019/07/02 06:00
PHST- 2019/02/19 00:00 [received]
PHST- 2019/04/07 00:00 [accepted]
PHST- 2019/07/02 06:00 [entrez]
PHST- 2019/07/02 06:00 [pubmed]
PHST- 2020/08/15 06:00 [medline]
AID - S1029-2977-22(05)232-0 [pii]
PST - epublish
SO  - Arch Iran Med. 2019 May 1;22(5):232-235.